Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra Supplement Safety To Be Revisited At Senate Subcommittee Hearing

This article was originally published in The Tan Sheet

Executive Summary

An "independent analysis" of 14,700 ephedra-related adverse event reports received by Metabolife International will be discussed by the Senate Governmental Affairs/Oversight of Government Management Subcommittee during a hearing slated for Oct. 8

You may also be interested in...

Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records

An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events

Ephedra “Imminent Hazard” Declaration Sought By Sen. Durbin

Sen. Dick Durbin (D-Ill.) is pressing HHS Secretary Tommy Thompson to take immediate action against the sale of ephedra weight-loss dietary supplements by declaring the herbal ingredient an "imminent hazard.

Herbal Regulatory Category Creation At FDA Suggested By Sen. Durbin

Sen. Dick Durbin (D-Ill.) is exploring the concept of a new regulatory scheme for dietary supplements that would create a separate regulatory category for herbal products


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts